ADRO - Aduro BioTech, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7400
+0.0100 (+0.37%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.7300
Open2.7200
Bid2.41 x 3100
Ask2.98 x 4000
Day's Range2.6900 - 2.7800
52 Week Range2.4700 - 9.9250
Volume414,278
Avg. Volume715,534
Market Cap217.567M
Beta (3Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-1.22
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.32
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity

    Aduro Biotech, Inc. (ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and Novartis collaborators as part of their ongoing research to study intratumoral stimulator of interferon genes (STING) pathway activation as a potential therapeutic approach for the treatment of cancer. In this study, researchers determined an intratumoral dosing regimen of STING pathway activator, ADU-S100, optimized for adaptive immunity in mouse models. While high doses of ADU-S100 were effective at clearing injected tumors, researchers found that higher tumor ablative dosing regimens could compromise durable anti-tumor immunity.

  • Aduro Biotech Enters Oversold Territory
    Zacks12 days ago

    Aduro Biotech Enters Oversold Territory

    Aduro Biotech has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire14 days ago

    Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition

    Aduro Biotech, Inc. (ADRO) today announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301 supporting its potential use as a treatment for multiple myeloma (MM) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. Data from the studies demonstrated that therapies blocking a proliferation inducing ligand (APRIL) from binding to B cell maturation antigen (BCMA) and transmembrane activator and cyclophilin ligand interactor (TACI) may simultaneously target MM cells and APRIL-induced immunosuppression. “Our newest findings from the data presented at ASH indicate that combining an anti-APRIL antibody such as BION-1301, which inhibits APRIL binding to TACI and BCMA, with a BCMA-targeted therapy may have the potential to augment anti-myeloma activity,” commented Dr. Kenneth C. Anderson, director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute.

  • GlobeNewswirelast month

    Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas

    Aduro Biotech, Inc. (ADRO) today announced presentation of preliminary data from its ongoing Phase 1 dose-finding study of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator, at SITC's 33rd Annual Meeting in Washington, D.C. Aduro and collaborator Novartis embarked on this first-in-human trial (see www.clinicaltrials.gov, identifier NCT02675439) as an important first step in characterizing the safety profile and mechanism of ADU-S100 and its ability to activate the STING pathway. The Phase 1 dose escalation and dose expansion clinical trial is designed to evaluate the safety, tolerability and clinical activity of ADU-S100 in patients with advanced, metastatic treatment-refractory solid tumors or lymphomas.

  • GlobeNewswirelast month

    Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Aduro Biotech, Inc. (ADRO) today announced that the company will host and webcast an investor event on Friday, November 9, 2018 at 6:30 p.m. Eastern Time in Washington, D.C. The event will feature special guest speaker Jason J. Luke, M.D., FACP, Assistant Professor of Medicine at the University of Chicago and a principal investigator for the Phase 1 dose-finding studies of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator. The archived webcast will remain available for replay on Aduro’s website for 30 days.

  • GlobeNewswirelast month

    New Research: Key Drivers of Growth for Shutterfly, Aegion, Columbia Property Trust, Aduro Biotech, IQVIA, and Intelsat S.A — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag
    Zacks2 months ago

    Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag

    Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.

  • Aduro Biotech (ADRO) Reports Q3 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Aduro Biotech (ADRO) Reports Q3 Loss, Misses Revenue Estimates

    Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.45% and -33.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire2 months ago

    Aduro Biotech Reports Third Quarter 2018 Financial Results

    BERKELEY, Calif., Oct. 30, 2018 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the third quarter ended September 30, 2018. Net loss for the third.

  • GlobeNewswire2 months ago

    Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018

    Aduro Biotech, Inc. (ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the treatment of IgA nephropathy (IgAN) at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA. IgAN is a progressive kidney disease characterized by an autoimmune antibody response against endogenous IgA. Preclinical studies demonstrated that BION-1301 binds to a specifically defined epitope on APRIL, resulting in complete blockade of APRIL induced receptor activation, and is expected to lead to suppression of IgA and the autoimmune response to IgA associated with the disease.

  • Aduro Biotech (ADRO) Q3 Earnings Preview: What's in the Cards?
    Zacks2 months ago

    Aduro Biotech (ADRO) Q3 Earnings Preview: What's in the Cards?

    Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why Aduro Biotech Crashed 29.5% Today
    Motley Fool2 months ago

    Why Aduro Biotech Crashed 29.5% Today

    Expectations are falling for a key drug in its pipeline.

  • GlobeNewswire3 months ago

    Aduro Biotech Announces Four Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Aduro Biotech, Inc. (ADRO) today announced that four separate abstracts from its research and development portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. from November 7-11, 2018. Preliminary clinical data from the ongoing Phase 1 dose-finding study evaluating ADU-S100 (MIW815), an intratumoral STING agonist in patients with advanced solid tumors or lymphomas, were accepted for presentation on November 9, 2018. “We look forward to sharing preliminary clinical data from the dose escalation portion of the monotherapy trial which provides an initial understanding of the potential role of ADU-S100 in the treatment of cancer and which contribute to the broader scientific understanding of the STING pathway,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro Biotech.

  • GlobeNewswire3 months ago

    Aduro Biotech to Present at Two Investor Conferences in October

    Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.

  • GlobeNewswire3 months ago

    Aduro Biotech Announces the Departure of Natalie R. Sacks, M.D.

    Aduro Biotech, Inc. (ADRO) today announced that Natalie R. Sacks, M.D. has resigned from her position as the company’s chief medical officer effective October 1, 2018. “On behalf of the management team and Board of Directors, I’m grateful for the significant contributions Natalie made over the past three years and we wish her the best in her next endeavor,” commented Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “During her tenure, Natalie has played an integral role in defining the development strategy for our lead STING agonist ADU-S100 and for our anti-APRIL antibody BION-1301, two first-in-class assets that have potential to impact the treatment landscape for patients with a myriad of serious diseases.

  • Implied Volatility Surging for Aduro BioTech (ADRO) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Aduro BioTech (ADRO) Stock Options

    Aduro BioTech (ADRO) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Are Insiders Cautious About Aduro BioTech Inc (NASDAQ:ADRO) Shares?
    Simply Wall St.3 months ago

    Are Insiders Cautious About Aduro BioTech Inc (NASDAQ:ADRO) Shares?

    Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. Aduro BioTech’s insiders have divested from 53.11k sharesRead More...

  • Aduro Biotech (ADRO) Up 17.4% Since Last Earnings Report: Can It Continue?
    Zacks4 months ago

    Aduro Biotech (ADRO) Up 17.4% Since Last Earnings Report: Can It Continue?

    Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Aduro Biotech (ADRO) Reports Q2 Loss, Lags Revenue Estimates
    Zacks5 months ago

    Aduro Biotech (ADRO) Reports Q2 Loss, Lags Revenue Estimates

    Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.06% and -29.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 months ago

    Aduro Biotech: 2Q Earnings Snapshot

    On a per-share basis, the Berkeley, California-based company said it had a loss of 31 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...